• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Matt Salo Explains How High-Cost Specialty Drugs Change the Game for Medicaid

Video

The high cost of Gilead Science's hepatitis C drug Sovaldi is causing Medicaid to come up with new ways of handling drug costs, according to Matt Salo, executive director of the National Association of Medicaid Directors.

The high cost of Gilead Science’s hepatitis C drug Sovaldi is causing Medicaid to come up with new ways of handling such an expensive drug, according to Matt Salo, executive director of the National Association of Medicaid Directors.

He discussed high-cost specialty drugs and their effect on Medicaid at the America’s Health Insurance Plans National Conferences on Medicare and Medicaid, and Dual Eligibles Summit in Washington, DC, from September 28 to October 2.

“[Sovaldi is] great from a public health perspective; but when you multiply large unit cost times a very large number of people, this drug alone has the potential of doubling Medicaid’s pharmacy spend,” Mr Salo said.

Related Videos
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Andrew Kuykendall, MD, Moffitt Cancer Center
Anna Mueller, MD, Mount Sinai
Marc Humbert, MD, PhD
Susan Cantrell, CEO of AMCP
John Ostrominski, MD
John Buse, MD, PhD
Marc P. Bonaca, MD, MPH
Christian T. Ruff, MD, MPH
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.